Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration

TY - JOUR

T1 - Breast cancer in 2013

T2 - Genomics, drug approval, and optimal treatment duration

AU - Lee, Adrian V.

AU - Davidson, Nancy E.

N1 - Funding Information: The work by the authors is supported in part by the National Cancer Institute of the NIH awards P30CA047904 (N. E. Davidson) and R01CA94118 (A. V. Lee). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors are also supported by funding through the Breast Cancer Research Foundation (N. E. Davidson and A. V. Lee), Susan G. Komen for the Cure (A. V. Lee), and the Pennsylvania Department of Health (N. E. Davidson and A. V. Lee). The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions.

PY - 2014/2

Y1 - 2014/2

UR - http://www.scopus.com/inward/record.url?scp=84895902343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895902343&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2013.250

DO - 10.1038/nrclinonc.2013.250

M3 - Review article

C2 - 24419301

AN - SCOPUS:84895902343

SN - 1759-4774

VL - 11

SP - 71

EP - 72

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 2

ER -